rheumatology
Medicines

Patients are willing to switch to a biosimilar – if the message is right


A patient’s willingness to switch from an originator to biosimilar molecule is influenced by how the physician frames the discussion, rheumatologists in New Zealand have shown. Patients given a positively framed brief explanation about biosimilars that emphasises the similarities with originator...

A patient’s willingness to switch from an originator to biosimilar molecule is influenced by how the physician frames the discussion,...

Read more